Dow R&D increased by 4.6% to $181.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 9.5%, from $200.00M to $181.00M. Over 4 years (FY 2021 to FY 2025), R&D shows a downward trend with a -3.2% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $228.00M | $210.00M | $225.00M | $218.00M | $217.00M | $191.00M | $225.00M | $214.00M | $205.00M | $197.00M | $213.00M | $204.00M | $196.00M | $208.00M | $202.00M | $200.00M | $188.00M | $191.00M | $173.00M | $181.00M |
| QoQ Change | — | -7.9% | +7.1% | -3.1% | -0.5% | -12.0% | +17.8% | -4.9% | -4.2% | -3.9% | +8.1% | -4.2% | -3.9% | +6.1% | -2.9% | -1.0% | -6.0% | +1.6% | -9.4% | +4.6% |
| YoY Change | — | — | — | — | -4.8% | -9.0% | +0.0% | -1.8% | -5.5% | +3.1% | -5.3% | -4.7% | -4.4% | +5.6% | -5.2% | -2.0% | -4.1% | -8.2% | -14.4% | -9.5% |